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BACKGROUND
The effect of decompressive craniectomy on clinical outcomes in patients with 
refractory traumatic intracranial hypertension remains unclear.
METHODS
From 2004 through 2014, we randomly assigned 408 patients, 10 to 65 years of age, 
with traumatic brain injury and refractory elevated intracranial pressure (>25 mm Hg) 
to undergo decompressive craniectomy or receive ongoing medical care. The pri-
mary outcome was the rating on the Extended Glasgow Outcome Scale (GOS-E) 
(an 8-point scale, ranging from death to “upper good recovery” [no injury-related 
problems]) at 6 months. The primary-outcome measure was analyzed with an or-
dinal method based on the proportional-odds model. If the model was rejected, 
that would indicate a significant difference in the GOS-E distribution, and results 
would be reported descriptively.
RESULTS
The GOS-E distribution differed between the two groups (P<0.001). The proportion-
al-odds assumption was rejected, and therefore results are reported descriptively. At 
6 months, the GOS-E distributions were as follows: death, 26.9% among 201 pa-
tients in the surgical group versus 48.9% among 188 patients in the medical group; 
vegetative state, 8.5% versus 2.1%; lower severe disability (dependent on others for 
care), 21.9% versus 14.4%; upper severe disability (independent at home), 15.4% versus 
8.0%; moderate disability, 23.4% versus 19.7%; and good recovery, 4.0% versus 6.9%. 
At 12 months, the GOS-E distributions were as follows: death, 30.4% among 194 
surgical patients versus 52.0% among 179 medical patients; vegetative state, 6.2% 
versus 1.7%; lower severe disability, 18.0% versus 14.0%; upper severe disability, 13.4% 
versus 3.9%; moderate disability, 22.2% versus 20.1%; and good recovery, 9.8% versus 
8.4%. Surgical patients had fewer hours than medical patients with intracranial pres-
sure above 25 mm Hg after randomization (median, 5.0 vs. 17.0 hours; P<0.001) but 
had a higher rate of adverse events (16.3% vs. 9.2%, P = 0.03).
CONCLUSIONS
At 6 months, decompressive craniectomy in patients with traumatic brain injury and 
refractory intracranial hypertension resulted in lower mortality and higher rates of 
vegetative state, lower severe disability, and upper severe disability than medical 
care. The rates of moderate disability and good recovery were similar in the two 
groups. (Funded by the Medical Research Council and others; RESCUEicp Current 
Controlled Trials number, ISRCTN66202560.)
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A fter traumatic brain injury (TBI), intracranial pressure can be elevated owing to a mass effect from intracranial hemato-
mas, contusions, diffuse brain swelling, or hydro-
cephalus.1 Intracranial hypertension can lead to 
brain ischemia by reducing the cerebral perfusion 
pressure.2 Intracranial hypertension after TBI is 
associated with an increased risk of death in most 
studies.3,4 The monitoring of intracranial pressure 
and the administration of interventions to lower 
intracranial pressure are routinely used in patients 
with TBI, despite the lack of level 1 evidence.5
Decompressive craniectomy is a surgical pro-
cedure in which a large section of the skull is re-
moved and the underlying dura mater is opened.6 
Primary decompressive craniectomy refers to leav-
ing a large bone flap out after the evacuation of 
an intracranial hematoma in the early phase af-
ter a TBI.7,8 Cranial reconstruction is undertaken 
a few weeks to months later with autologous 
bone (the removed bone flap is stored in the pa-
tient’s abdominal wall or a freezer) or an implant 
(titanium or other synthetic material). A second-
ary decompressive craniectomy is used as part of 
tiered therapeutic protocols that are frequently 
used in intensive care units (ICUs) in order to con-
trol raised intracranial pressure and to ensure ad-
equate cerebral perfusion pressure after TBI.7,8 For 
example, in the Decompressive Craniectomy 
(DECRA) trial,9 patients who had an intracranial 
pressure of more than 20 mm Hg for more than 
15 minutes (continuously or intermittently) with-
in a 1-hour period, despite optimized first-tier 
interventions, were randomly assigned to early 
bifrontal decompressive craniectomy and stan-
dard care or to standard care alone. The authors 
found that decompressive craniectomy was associ-
ated with more unfavorable outcomes than stan-
dard care alone. Alternatively, craniectomy can be 
performed as a last-tier intervention when the 
intracranial pressure remains elevated despite all 
other measures.10,11 We conducted the Randomised 
Evaluation of Surgery with Craniectomy for Un-
controllable Elevation of Intracranial Pressure 
(RESCUEicp) trial to assess the effectiveness of 
craniectomy as a last-tier intervention in patients 
with TBI and refractory intracranial hypertension.
Me thods
Trial Design and Oversight
In this international, multicenter, parallel-group, 
superiority, randomized trial, we compared last-
tier secondary decompressive craniectomy with 
continued medical management for refractory in-
tracranial hypertension after TBI. Ethics approval 
in the United Kingdom was obtained in 2003 
from the Cambridgeshire 4 research ethics com-
mittee (formerly known as the Eastern multicenter 
research ethics committee); ethics committees at 
all other participating institutions also approved 
the trial.
Because the trial enrolled patients with severe 
TBI, written informed consent was obtained from 
the nearest relative or a person who had been 
designated to give consent on admission of the 
patient. An independent steering committee and 
an independent data monitoring and ethics com-
mittee reviewed the trial regularly to assess con-
duct, progress, and safety.
The trial protocol, available with the full text 
of this article at NEJM.org, was designed in a 
collaborative fashion by the Divisions of Neuro-
surgery and Anaesthesia at the University of Cam-
bridge, collaborating clinicians, and the Euro-
pean Brain Injury Consortium. Full details of the 
protocol have been published previously.11 The 
investigators vouch for the completeness and ac-
curacy of the data and the analyses and for the 
fidelity of this report to the trial protocol and the 
statistical analysis plan.
Participants and Trial Sites
To undergo randomization in the trial, patients 
had to be between 10 and 65 years of age, have 
a TBI with an abnormal computed tomographic 
(CT) scan of the brain, have an intracranial-pressure 
monitor already in place, and have raised intra-
cranial pressure (>25 mm Hg for 1 to 12 hours, 
despite stage 1 and 2 measures, as defined be-
low and in Fig. 1). Patients who had undergone 
an immediate operation for evacuation of an 
intracranial hematoma could be included as long 
as the operation was not a craniectomy (i.e., the 
bone flap was replaced at the end of procedure). 
Patients with bilateral fixed and dilated pupils, 
bleeding diathesis, or an injury that was deemed 
to be unsurvivable were excluded. Trial sites were 
hospitals that provide acute neurosciences care 
for patients with severe TBI and that have 24-hour 
neurosurgical services (see the Supplementary Ap-
pendix, available at NEJM.org).
Interventions and Randomization
Patients were treated in ICUs according to a pro-
tocol that was aimed at maintaining an intracra-
A Quick Take 
is available at 
NEJM.org
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nial pressure of 25 mm Hg or less by applying 
treatments in a stepwise manner (Fig. 1). The 
initial stage (stage 1) included sedation, analge-
sia, and head elevation; neuromuscular paralysis 
was optional. Other targets included a cerebral 
perfusion pressure (the difference between the 
mean blood pressure and intracranial pressure) 
of more than 60 mm Hg, normothermia, normo-
glycemia, mild hypocapnia (partial pressure of 
arterial carbon dioxide [PaCO2], 4.5 to 5.0 kPa 
[34 to 38 mm Hg]), and adequate oxygenation 
(oxygen saturation, >97%). If the intracranial pres-
sure was not controlled, stage 2 options included 
ventriculostomy (if an external ventricular drain 
had not already been inserted for intracranial-
pressure monitoring), pharmacologic blood-pres-
sure augmentation, osmotherapy, moderate hypo-
capnia (PaCO2, 4.0 to 4.5 kPa [30 to 34 mm Hg]), 
and therapeutic hypothermia (not <34°C).
If the intracranial pressure remained above 
25 mm Hg for 1 to 12 hours despite these mea-
sures, then at stage 3 of the protocol, patients 
were randomly assigned to undergo decompres-
sive craniectomy with medical therapy or to receive 
continued medical therapy with the option of 
adding barbiturates to reduce the intracranial 
pressure. Patients underwent randomization, in 
a 1:1 ratio, with the use of permuted blocks of 
random sizes and with stratification according 
to trial site. To ensure concealment, the block 
sizes were not disclosed. Participants underwent 
randomization with the use of a central telephone 
randomization service. Concealment of the trial-
group assignments was ensured, because the ser-
vice did not release the randomization code until 
the patient had reached stage 3 of the protocol.
The surgical treatment was either large uni-
lateral frontotemporoparietal craniectomy (hemi-
craniectomy), which was recommended for pa-
tients with unilateral hemispheric swelling, or 
bifrontal craniectomy, which was recommended 
for patients with diffuse brain swelling that af-
fected both hemispheres on imaging studies. 
The exact type of craniectomy was left to the dis-
cretion of the surgeons. Details of the recom-
mended surgical technique are provided in the 
protocol. In addition, it was recommended that 
surgery should be performed no later than 4 to 
6 hours after randomization.
Patients who were assigned to receive medical 
treatment alone could undergo a decompressive 
craniectomy later in case their condition deterio-
rated further, at the discretion of treating clini-
cians. Similarly, patients who were assigned to 
undergo decompressive craniectomy could have 
barbiturate infusion in case of further deteriora-
tion of their condition.
Outcomes
The primary-outcome measure was assessed with 
the use of the Extended Glasgow Outcome Scale 
(GOS-E) at 6 months after randomization.12 The 
GOS-E is a global outcome scale assessing func-
tional independence, work, social and leisure 
activities, and personal relationships. Its eight 
outcome categories are as follows: death, vegeta-
tive state (unable to obey commands), lower se-
Figure 1. Stages of Therapeutic Management.
Agreement for participation was obtained from the nearest relative or a 
person who had been designated to give consent preemptively on admis-
sion of the patient in order to avoid delays in treatment. Randomization 
was performed after stage 2 if the intracranial pressure was more than  
25 mm Hg for 1 to 12 hours. The protocol stages 1 and 2 reflected the 
therapeutic protocols that were followed in the participating units.
Intracranial pressure >25 mm Hg
for 1–12 hr
Continue stage 1 treatments
Barbiturates not permitted
Optional treatments that can 
be added
Ventriculostomy
Inotropes
Mannitol
Hypertonic saline
Loop diuretics
Hypothermia
Intracranial pressure >25 mm Hg
Initial treatment measures
Head elevation
Ventilation
Sedation
Analgesia
Paralysis (optional)
Monitoring
Central venous pressure
Arterial blood pressure
Intracranial pressure
Surgical group
Decompressive craniectomy
Continue stage 1 and 2 treatments
Medical group
Continue stage 1 and 2 treatments
Barbiturates permitted
Stage 1
Stage 3
Stage 2
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vere disability (dependent on others for care), upper 
severe disability (independent at home), lower 
moderate disability (independent at home and out-
side the home but with some physical or mental 
disability), upper moderate disability (independent 
at home and outside the home but with some 
physical or mental disability, with less disrup-
tion than lower moderate disability), lower good 
recovery (able to resume normal activities with 
some injury-related problems), and upper good 
recovery (no problems). Details are provided in 
the Supplementary Appendix.
In the United Kingdom, the trial office in 
Cambridge mailed the GOS-E questionnaires to 
surviving participants. If no response was received, 
a trial team member contacted the patient or a 
caregiver by telephone to complete the question-
naire. At international sites, local staff were re-
sponsible for the above processes. Two trial team 
investigators, who were unaware of the trial-group 
assignments, centrally adjudicated outcomes on 
the basis of the GOS-E questionnaires indepen-
dently of each other according to a standardized 
approach.13 Disagreements were resolved by con-
sensus between them or with the consultation of 
a third trial team investigator who was also un-
aware of the trial-group assignments.
The secondary outcomes were the following: 
GOS-E results at 12 and 24 months after random-
ization; mortality at 6, 12, and 24 months after 
randomization; quality of life at 6, 12, and 24 
months after randomization; Glasgow Coma Scale 
(GCS) score at discharge from the neurosciences 
hospital; assessment of intracranial-pressure 
control; time in the ICU; time to discharge from 
the neurosciences hospital; and economic evalu-
ation. Quality of life was assessed with the 36-item 
Short-Form Health Survey in adults and the 10-item 
Short-Form Health Survey in children. Assessment 
of intracranial-pressure control included the mean 
intracranial pressure in the period after random-
ization, the number of hours with the intracranial 
pressure above 25 mm Hg in the period after ran-
domization, the intracranial hypertension index 20 
(the number of end-hourly measures of intracra-
nial pressure of >20 mm Hg divided by the total 
number of measurements, multiplied by 100), 
the intracranial hypertension index 25 (the num-
ber of end-hourly measures of intracranial pres-
sure of >25 mm Hg divided by the total number 
of measurements, multiplied by 100), and the ce-
rebral hypoperfusion index (the number of end-
hourly measures of cerebral perfusion pressure 
of <60 mm Hg divided by the total number of 
measurements, multiplied by 100). Data on com-
plications and serious adverse events were also 
collected.
Statistical Analysis
We calculated that a target sample of 400 patients 
would allow us to detect a treatment effect of 
15 percentage points between the two groups 
(difference in favorable-outcome rate of 45% vs. 
60%; see the definition of favorable outcome 
later in this section) with 80% power at the 5% 
significance level (two-sided), allowing for a loss 
to follow-up of up to 15%.11 The analysis was per-
formed according to a statistical analysis plan, 
which was agreed on without reference to the 
unblinded data (see the protocol).14
Outcomes were reported in the intention-to-
treat population, which was modified to exclude 
patients who were lost to follow-up or who with-
drew consent. Missing outcome data were not im-
puted. As prespecified in the statistical analysis 
plan, a sensitivity analysis was performed for the 
primary-outcome measure in the per-protocol 
population. The per-protocol population was de-
fined as the patients in the intention-to-treat 
population who did not have a severe breach of 
protocol.
The primary-outcome measure was analyzed 
with an ordinal analysis method that was based 
on the proportional-odds model.15 The goodness 
of fit of the unadjusted proportional-odds models 
was tested with the use of a likelihood-ratio test. 
The rejection of the proportional-odds model at 
the 5% significance level indicated a difference 
in the GOS-E distribution between the two ran-
domized groups. In this situation, the presenta-
tion of the results was prespecified to describe 
the difference in outcomes between the groups, 
and the groups were compared formally with the 
use of an unordered chi-square test. For the pri-
mary analysis, the GOS-E categories of upper good 
recovery and lower good recovery were pooled, 
since a blinded review of the distribution of 
GOS-E ratings revealed that there were too few 
patients in these categories for them to be ana-
lyzed separately.
In a prespecified sensitivity analysis, we com-
pared the proportion of patients who had an out-
come of upper severe disability or better on the 
GOS-E scale (“favorable outcome”) between the 
The New England Journal of Medicine 
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randomized groups, using a chi-square test. Con-
ventionally, the GOS-E scale is dichotomized so 
that upper severe disability is categorized as be-
ing an unfavorable outcome, together with veg-
etative state and lower severe disability. Patients 
who are in the category of upper severe disability 
are largely independent around their homes but 
need assistance with traveling or shopping, where-
as patients who are in the category of lower severe 
disability live in a supervised facility (care facil-
ity) or, if at home, need assistance most of the 
time. In view of the anticipated high proportion 
of poor outcomes in this trial population, it was 
agreed a priori by the trial team and the steering 
committee that the upper-severe-disability cate-
gory would be included in the definition of fa-
vorable outcome. A similar approach has been 
followed in some trials of craniectomy for mid-
dle-cerebral-artery infarction, in which moder-
ately severe disability (modified Rankin scale 
score, 4 [unable to walk without assistance and 
unable to attend to own bodily needs without as-
sistance]) was categorized as a favorable outcome, 
although most stroke trials conventionally cate-
gorize it as unfavorable.16,17
Prespecified exploratory analyses examined the 
effect of covariate adjustment (age, GCS motor 
score, pupillary reactivity, and the Marshall grade 
of the last available prerandomization CT of the 
brain) on the analyses described above. The du-
ration of ICU stay was analyzed with the use of 
Kaplan–Meier estimates and log-rank tests. The 
time to discharge from the neurosciences hospi-
tal and the GCS score at discharge from the 
neurosciences hospital were not analyzed because 
the data were not collected. Instead, the GCS 
score at the time of discharge from the ICU was 
available and was analyzed with the use of the 
same ordinal method as described above for the 
GOS-E. All other analyses of categorical data were 
based on chi-square tests, and analyses of con-
tinuous variables were based on Mann–Whitney 
U tests. The GOS-E ratings at 24 months, quali-
ty-of-life data, and the planned economic evalu-
ation have not yet been analyzed.
R esult s
Recruitment and Characteristics  
of the Patients
The first patient was enrolled in January 2004, 
and the trial was closed to recruitment in March 
2014, when the intended sample size was reached. 
A total of 2008 patients were assessed for trial 
eligibility, and 409 patients at 52 centers in 20 
countries underwent randomization; of these pa-
tients, 291 (71.1%) were recruited in the United 
Kingdom. One patient underwent randomization 
twice in error, therefore leaving 408 patients. Of 
these patients, 206 were assigned to the surgical 
group and 202 to the medical group (see the 
Supplementary Appendix). Five patients were 
excluded from the analysis owing to withdraw-
al of consent, and 5 were excluded owing to a 
lack of valid informed consent, leaving 202 pa-
tients in the surgical group and 196 in the medi-
cal group. Of the 398 remaining patients, 389 
were evaluated for the primary outcome (201 pa-
tients in the surgical group and 188 in the medi-
cal group), and 373 were evaluated at 12 months 
(194 in the surgical group, and 179 in the medi-
cal group). The characteristics of the two groups 
were similar at baseline, except that fewer patients 
in the surgery group than in the medical group 
had a history of drug or alcohol abuse (Table 1).
Interventions
Similar numbers of patients in the two groups re-
ceived stage 1 and stage 2 treatments that had 
been designated as optional (Table 2). No signifi-
cant between-group differences were observed in 
the rate of craniotomies performed before random-
ization or in the type of evacuated hematomas.
In the surgical group, 92.6% of the patients 
underwent decompressive craniectomy (Table 2). 
The median time from randomization to crani-
ectomy was 2.2 hours.
In the medical group, 87.2% of the patients 
received a barbiturate infusion (Table 2). The me-
dian time from randomization to barbiturate 
infusion was 1.5 hours. The median duration of 
barbiturate therapy was 53 hours. Decompressive 
craniectomy was performed in 37.2% of the pa-
tients in the medical group. (See Tables S3 and 
S8 in the Supplementary Appendix.)
Outcomes
Primary Outcome
In a modified intention-to-treat analysis, the pre-
specified ordinal regression showed evidence of a 
difference in the 6-month GOS-E distribution be-
tween the two groups (χ2 = 7.72, 1 df, P = 0.005). 
However, the goodness-of-fit test rejected the pro-
portional-odds assumption that underlies the 
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ordinal regression analysis (χ2 = 22.86, 5 df, 
P<0.001). Therefore, the common odds ratio 
could not be used to describe the direction and 
magnitude of the treatment effect that was ob-
served with the ordinal regression. Hence, as 
prespecified, the remaining analyses aimed to 
describe the way in which the distribution of 
GOS-E ratings differed between the two ran-
domized groups. The unordered test comparing 
the distribution of the GOS-E ratings over the 
two groups yielded a χ2 of 30.69 (7 df, P<0.001).
At 6 months after randomization, the GOS-E 
distributions were as follows: death, 26.9% 
among 201 patients in the surgical group and 
48.9% among 188 patients in the medical group; 
vegetative state, 8.5% versus 2.1%; lower severe 
disability (dependent on others for care), 21.9% 
versus 14.4%; upper severe disability (independent 
at home), 15.4% versus 8.0%; moderate disability, 
23.4% versus 19.7%; and good recovery, 4.0% 
versus 6.9% (Table 3 and Fig. 2). In a prespecified 
sensitivity analysis, favorable outcomes (prespeci-
fied as upper severe disability or better on the 
GOS-E) occurred in 42.8% of the patients in the 
surgical group and in 34.6% of those in the medi-
cal group (P = 0.12) (Fig. S1 in the Supplementary 
Appendix). Using the absolute differences presented 
in Table 3, we estimated that for every 100 patients 
treated with surgical rather than medical intent, 
there were 22 more survivors; of these 22 patients, 
6 were in a vegetative state (27%), 8 were catego-
rized as having lower severe disability (36%), and 
8 were categorized as having upper severe dis-
ability or better (36%).
Secondary Outcomes
At 12 months after randomization, the GOS-E 
distributions were as follows: death, 30.4% among 
194 patients in the surgical group versus 52.0% 
among 179 patients in the medical group; vege-
tative state, 6.2% versus 1.7%; lower severe dis-
ability, 18.0% versus 14.0%; upper severe disability, 
13.4% versus 3.9%; moderate disability, 22.2% 
versus 20.1%; and good recovery, 9.8% versus 8.4% 
Characteristic
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Age — yr 32.3±13.2 34.8±13.7
Male sex — no./total no. (%) 165/202 (81.7) 156/195 (80.0)
GCS motor score at first hospital — no./total no. (%)†
1 or 2 96/181 (53.0) 85/170 (50.0)
3–6 85/181 (47.0) 85/170 (50.0)
Pupillary abnormality — no. (%)‡ 59 (29.2) 57 (29.1)
Hypotension — no. (%)§ 40 (19.8) 42 (21.4)
Hypoxemia — no. (%)¶ 49 (24.3) 52 (26.5)
History of drug or alcohol abuse — no. (%) 50 (24.8) 69 (35.2)
Extracranial injury — no. (%) 75 (37.1) 83 (42.3)
Injury classification on basis of CT imaging — no./total no. (%)‖
Diffuse injury 161/198 (81.3) 141/186 (75.8)
Mass lesion 37/198 (18.7) 45/186 (24.2)
*  Plus–minus values are means ±SD. There were no significant between-group differences in these baseline characteris-
tics except for history of drug or alcohol abuse (P = 0.02). Additional baseline data are provided in Tables S1, S2, and 
S4 through S7 in the Supplementary Appendix.
†  A Glasgow Coma Scale (GCS) motor score of 1 indicates that the patient makes no movements to painful stimuli,  
2 has extension, 3 has abnormal flexion, 4 has normal flexion, 5 localizes to painful stimuli, and 6 obeys commands.
‡  Pupil abnormality was defined as the presence of unreactive pupils or anisocoria.
§  Hypotension was defined as a systolic blood pressure of less than 90 mm Hg.
¶  Hypoxemia was defined as a partial pressure of arterial oxygen of less than 8 kPa (60 mm Hg).
‖  Injury classification was determined on the basis of the Marshall classification of the prerandomization CT image of the 
head (Table S5 in the Supplementary Appendix). If the prerandomization CT image of the head was not available, the 
classification was done on the basis of the Marshall classification of the initial CT of the head, taking into account 
whether a craniotomy for evacuation of a mass lesion had occurred before randomization.
Table 1. Characteristics of the Patients at Baseline.*
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(Table 3 and Fig. 2). In a prespecified sensitivity 
analysis, favorable outcomes (upper severe dis-
ability or better) occurred in 45.4% of the patients 
in the surgical group, as compared with 32.4% 
of those in the medical group (P = 0.01). Using 
the absolute differences presented in Table 3, we 
estimated that for every 100 patients treated with 
surgical rather than medical intent, there were 22 
more survivors; of these 22 patients, 5 were in a 
vegetative state (23%), 4 were categorized as 
having lower severe disability (18%), and 13 were 
categorized as having upper severe disability or 
better (59%). Adjustment of the GOS-E ratings at 
6 months and at 12 months for the prespecified 
covariates did not alter the results. (Details are 
provided in Fig. S2 and Tables S12 and S16 in the 
Supplementary Appendix.)
Similar to the GOS-E results at 6 months, the 
goodness-of-fit test rejected the proportional-
odds assumption in analyses of the GCS scores 
(χ2 = 10.79, 3 df, P = 0.01); descriptive results are 
shown in Table 3. Control of intracranial pres-
sure was better in the surgical group than in the 
medical group, as shown by the significant dif-
ferences in the five relevant prespecified measures 
(Table 3). There was no between-group difference 
in the median values of time to discharge (includ-
ing death) in the ICU. A time-to-event analysis of 
length of stay, with follow-up data censored at 
death for patients who died in the ICU, showed 
that the median time to discharge among survi-
vors was 15.0 days in the surgical group, as 
compared with 20.8 days in the medical group 
(P = 0.01). Adverse events were reported in 16.3% 
of the patients in the surgical group, as compared 
with 9.2% of those in the medical group 
(P = 0.03). (Details are provided in Tables S9, S10, 
S17, and S18 in the Supplementary Appendix.)
Four patients had a severe breach of protocol 
(intracranial pressure not monitored before ran-
domization in one patient in the surgical group, 
age outside the upper cutoff in two [one patient 
in each group], and uncorrected bleeding diathe-
sis in one in the surgical group) and were not in-
cluded in the per-protocol population. The per-
protocol analysis of the GOS-E results at 6 months 
did not alter the findings that were observed in 
the modified intention-to-treat analysis. A post 
hoc sensitivity analysis of the worst-case sce-
nario for mortality at 6 months did not alter the 
results. In a further sensitivity analysis, results 
were explored for six a priori subgroups. (See 
Tables S13, S14, and S15 in the Supplementary 
Appendix.)
Treatment or Intervention
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Craniotomy for evacuation of hematoma — no. (%) 26 (12.9) 30 (15.3)
Ventriculostomy — no. (%) 34 (16.8) 43 (21.9)
Neuromuscular paralysis — no. (%) 101 (50.0) 103 (52.6)
Pharmacologic blood-pressure augmentation — no. (%) 112 (55.4) 116 (59.2)
Osmotherapy — no. (%) 146 (72.3) 144 (73.5)
Therapeutic hypothermia — no. (%) 47 (23.3) 53 (27.0)
Decompressive craniectomy — no. (%)† 187 (92.6) 73 (37.2)
Bifrontal — no./total no. (%) 109/173 (63.0) NA
Unilateral — no./total no. (%) 64/173 (37.0) NA
Barbiturates — no. (%)‡ 19 (9.4) 171 (87.2)
*  There were no significant between-group differences with respect to therapeutic interventions administered before ran-
domization. Decompressive craniectomy and barbiturates were administered only in the period after randomization. 
NA denotes not applicable.
†  The reasons for not performing decompressive craniectomy were further deterioration of the patient, control of intra-
cranial pressure while waiting for surgery, uncorrected coagulopathy, and massive epistaxis on positioning of the pa-
tient. The type of decompressive craniectomy was unknown in 14 patients in the surgical group. Information on de-
compressive craniectomy was only collected in the surgical group.
‡  The median duration of barbiturate therapy in the medical group was 53 hours (interquartile range, 24.5 to 115). Data 
on the duration of therapy were available for 122 patients.
Table 2. Treatments and Interventions.*
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Variable
Surgical Group 
(N = 202)
Medical Group 
(N = 196)
Absolute Difference 
(95% CI)† P Value
percentage points
GOS-E result — no./total no. (%)‡ <0.001
At 6 mo
Death 54/201 (26.9) 92/188 (48.9) −22.1 (−31.5 to −12.7)
Vegetative state 17/201 (8.5) 4/188 (2.1) 6.3 (2.0 to 10.7)
Lower severe disability 44/201 (21.9) 27/188 (14.4) 7.5 (−0.1 to 15.1)
Upper severe disability 31/201 (15.4) 15/188 (8.0) 7.4 (1.1 to 13.8)
Lower moderate disability 20/201 (10.0) 19/188 (10.1) −0.1 (−6.1 to 5.8)
Upper moderate disability 27/201 (13.4) 18/188 (9.6) 3.9 (−2.5 to 10.2)
Lower good recovery 5/201 (2.5) 6/188 (3.2) −0.7 (−4.0 to 2.6)
Upper good recovery 3/201 (1.5) 7/188 (3.7) −2.2 (−5.4 to 1.0)
At 12 mo <0.001
Death 59/194 (30.4) 93/179 (52.0) −21.5 (−31.3 to −11.8)
Vegetative state 12/194 (6.2) 3/179 (1.7) 4.5 (0.6 to 8.4)
Lower severe disability 35/194 (18.0) 25/179 (14.0) 4.1 (−3.3 to 11.5)
Upper severe disability 26/194 (13.4) 7/179 (3.9) 9.5 (3.9 to 15.1)
Lower moderate disability 20/194 (10.3) 14/179 (7.8) 2.5 (−3.3 to 8.3)
Upper moderate disability 23/194 (11.9) 22/179 (12.3) −0.4 (−7.1 to 6.2)
Lower good recovery 14/194 (7.2) 7/179 (3.9) 3.3 (−1.3 to 7.9)
Upper good recovery 5/194 (2.6) 8/179 (4.5) −1.9 (−5.7 to 1.9)
GCS score or death at discharge from ICU — no./total no. (%)§ <0.001
Death 42/185 (22.7) 83/171 (48.5) −25.8 (−35.5 to −16.2)
GCS score
3–5 13/185 (7.0) 11/171 (6.4) 0.6 (−4.6 to 5.8)
6–8 22/185 (11.9) 10/171 (5.8) 6.0 (0.2 to 11.9)
9–12 67/185 (36.2) 37/171 (21.6) 14.6 (5.3 to 23.9)
13–15 41/185 (22.2) 30/171 (17.5) 4.6 (−3.6 to 12.9)
Intracranial-pressure control¶
Median mean intracranial pressure after randomization 
(IQR) — mm Hg
14.5 (1.7–18.0) 17.1 (4.2–21.8) −3.0 (−4.1 to −1.8) <0.001
Median duration of intracranial pressure >25 mm Hg 
after randomization (IQR) — hr
5.0 (0.0–17.0) 17.0 (5.0–35.0) −8.0 (−12.0 to −5.0) <0.001
Median intracranial hypertension index 20 (IQR) 18.1 (9.9–36.7) 31.4 (18.2–54.2) −10.4 (−14.5 to −6.7) <0.001
Median intracranial hypertension index 25 (IQR) 6.6 (3.1–13.6) 11.8 (5.6–27.8) −4.2 (−6.2 to −2.5) <0.001
Median cerebral hypoperfusion index 60 (IQR) 6.8 (3.1–16.6) 11.1 (4.4–24.8) −2.8 (−4.9 to −1.0) 0.002
*  ICU denotes intensive care unit, and IQR interquartile range.
†  Absolute differences between percent values are percentage points and may not sum exactly owing to rounding. For median values, the 
treatment groups were compared with the use of the Mann–Whitney U test and the corresponding confidence interval. The estimated differ-
ence between the median values is not simply the observed difference between the median values.
‡  P values for the comparisons of the Extended Glasgow Outcome Scale (GOS-E) results were calculated by means of unordered chi-square tests. 
The eight outcome categories on the GOS-E are death, vegetative state (unable to obey commands), lower severe disability (dependent on others 
for care), upper severe disability (independent at home), lower moderate disability (independent at home and outside the home but with some 
physical or mental disability), upper moderate disability (independent at home and outside the home but with some physical or mental disability, 
with less disruption than lower moderate disability), lower good recovery (able to resume normal activities with some injury-related problems), and 
upper good recovery (no problems). See the Supplementary Appendix for additional descriptions of the outcome categories.
§  The GCS was used for assessing impairment of the level of consciousness. Scores range from 3 to 15, with lower scores indicating greater 
impairment. The P value was calculated by means of an unordered chi-square test.
¶  The mean intracranial pressure after randomization and the duration of intracranial pressure of more than 25 mm Hg after randomization 
could be calculated for 165 patients in the surgical group and for 160 in the medical group. The three indexes could be calculated for 192 
patients in the surgical group and for 183 in the medical group. The intracranial hypertension index 20 is the number of end-hourly mea-
sures of intracranial pressure of more than 20 mm Hg divided by the total number of measurements, multiplied by 100. The intracranial hy-
pertension index 25 is the number of end-hourly measures of intracranial pressure of more than 25 mm Hg divided by the total number of 
measurements, multiplied by 100. The cerebral hypoperfusion index 60 is the number of end-hourly measures of cerebral perfusion pressure 
of less than 60 mm Hg divided by the total number of measurements, multiplied by 100.
Table 3. Analysis of Primary and Secondary Outcomes.*
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Discussion
In this trial involving patients with sustained 
and refractory intracranial hypertension after 
TBI, the GOS-E distributions at 6 months were 
as follows: death, 26.9% in the surgical group and 
48.9% in the medical group; vegetative state, 8.5% 
versus 2.1%; lower severe disability (dependent 
on others for care), 21.9% versus 14.4%; upper 
severe disability (independent at home), 15.4% 
versus 8.0%; moderate disability, 23.4% versus 
19.7%; and good recovery 4.0% versus 6.9%. The 
rate of an outcome of upper severe disability or 
better was 42.8% in the surgical group versus 
34.6% in the medical group.
The treatment protocol of the trial was orga-
nized in three hierarchical stages, with treatment 
intensity increasing at every stage. All stage 2 
interventions, neuromuscular paralysis (stage 1), 
and barbiturate infusion after randomization in 
the medical group were designated as optional 
in view of the lack of level 1 evidence regarding 
their efficacy at the time of trial initiation and 
during the conduct of the trial. This decision 
was in keeping with the pragmatic nature of the 
trial. The treatment protocol in this trial was 
also similar to the treatment protocol that was 
used in a trial of hypothermia for intracranial 
hypertension after TBI.18 The numbers of patients 
who received the optional stage 1 and stage 2 
interventions were similar in the two groups, a 
finding that suggests that concomitant interven-
tions were not responsible for the observed result.
In contrast to the present trial, the DECRA 
Figure 2. Stacked Bar Chart of Extended Glasgow Outcome Scale (GOS-E) Results at 6 Months and 12 Months.
The primary-outcome measure was assessed with the use of the GOS-E, a global outcome scale assessing function-
al independence, work, social and leisure activities, and personal relationships.12 The eight outcome categories are 
death, vegetative state (unable to obey commands), lower severe disability (dependent on others for care), upper 
severe disability (independent at home), lower moderate disability (independent at home and outside the home but 
with some physical or mental disability), upper moderate disability (independent at home and outside the home but 
with some physical or mental disability, with less disruption than lower moderate disability), lower good recovery 
(able to resume normal activities with some injury-related problems), and upper good recovery (no problems). See 
the Supplementary Appendix for additional descriptions of the outcome categories.
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trial9 showed that patients undergoing craniec-
tomy had worse ratings on the GOS-E at 6 months 
than those receiving standard care (P = 0.03), al-
though the rates of death were similar at 6 months 
(19% and 18%, respectively). The DECRA trial 
aimed to assess the effectiveness of early crani-
ectomy — offered as a stage 2 treatment within 
72 hours after injury — for moderate intracranial 
hypertension (intracranial pressure, >20 mm Hg 
for 15 minutes within a 1-hour period [continu-
ous or cumulative]) in patients with diffuse TBI.9 
The RESCUEicp trial aimed to assess the effec-
tiveness of decompressive craniectomy offered as 
a last-tier treatment.11 In addition, patients with 
intracranial hematoma (evacuated or nonevacu-
ated) were excluded from the DECRA trial, where-
as they represented almost 20% of the patients in 
the RESCUEicp trial. Moreover, unilateral de-
compressive craniectomy (hemicraniectomy) was 
not allowed by the protocol of the DECRA trial, 
whereas it was an option in the protocol of the 
RESCUEicp trial.
Our trial provides quantitative evidence to in-
form the debate around historical concerns that 
decompressive craniectomy simply increases the 
number of patients who survive in a vegetative 
state.8 The survival advantage of decompressive 
craniectomy in this trial was translated to both 
dependent and independent living. Clinicians and 
family members will need to be aware of this is-
sue when making decisions regarding treatment 
options. Improved control of intracranial pres-
sure with surgery may have accounted for mor-
tality that was lower than that observed with 
medical management, but our trial did not test 
this hypothesis.4
Some limitations of the present trial should 
be noted. First, the clinical teams who cared for 
the patients were aware of trial-group assign-
ments. However, outcome adjudication on the 
basis of the GOS-E questionnaires was done at 
the coordinating center by personnel who were 
unaware of the group assignments. Second, a rela-
tively large proportion of patients in the medical 
group underwent decompressive craniectomy; this 
situation may have diluted the observed treat-
ment effect. Third, 10 patients were excluded 
from all analyses owing to withdrawal of con-
sent or to a lack of valid consent, and 7 more 
patients in the medical group were lost to pri-
mary follow-up. Fourth, long-term data on cra-
nial reconstruction — a procedure that is usually 
necessary a few weeks to months after decom-
pressive craniectomy — were not systematically 
obtained owing to the pragmatic nature of the 
trial. This important aspect of treatment needs to 
be explored in future studies. Finally, the present 
trial did not examine the effectiveness of primary 
decompressive craniectomy, which is undertaken 
more frequently than secondary decompressive 
craniectomy.19,20
In conclusion, at 6 months, decompressive 
craniectomy for severe and refractory intracra-
nial hypertension after TBI resulted in mortality 
that was 22 percentage points lower than that 
with medical management. Surgery also was as-
sociated with higher rates of vegetative state, 
lower severe disability, and upper severe disabil-
ity than medical management. The rates of mod-
erate disability and good recovery with surgery 
were similar to those with medical management.
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